Literature DB >> 16357566

Chromosomal translocations in cancer and their relevance for therapy.

Tomohiko Taki1, Masafumi Taniwaki.   

Abstract

PURPOSE OF REVIEW: Recurring chromosomal abnormalities are considered the primary genetic change in oncogenesis as well as an important indicator for tumor phenotype and clinical outcome. This review highlights recent findings regarding the genes associated with chromosomal translocations. RECENT
FINDINGS: A great number of novel fusion genes associated with chromosomal translocations have been cloned. These novel fusion genes are found in the smaller part of various malignancies, and it can be expected that the significance of novel fusion gene occurrence for oncogenesis will be clarified in the not too distant future. Observation of high frequencies of mutations in NOTCH1, NPM and JAK2 in T-cell acute lymphoblastic leukemia, acute myeloid leukemia with normal karyotype and myeloproliferative disorders (polycythemia vera, essential thrombocythemia and idiopathic myelofibrosis) have provided important suggestions for a better understanding of chromosomal translocations. This is because all these genes had already been identified as genes associated with chromosomal translocations in a small subset of specific phenotypes of hematologic malignancies.
SUMMARY: This review summarizes recent findings associated with chromosomal translocations including newly identified fusion genes, a novel mechanism of fusion gene formation and their relevance for novel targeted therapies. Continuing attempts to identify genes associated with chromosomal translocations can be expected to provide further insights into the significance of various gene alterations in cancer and the development of novel targeted therapies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16357566     DOI: 10.1097/01.cco.0000198972.69541.04

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  7 in total

1.  Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers.

Authors:  Ashish B Rajput; Melinda A Miller; Alessandro De Luca; Niki Boyd; Sam Leung; Antonio Hurtado-Coll; Ladan Fazli; Edward C Jones; Jodie B Palmer; Martin E Gleave; Michael E Cox; David G Huntsman
Journal:  J Clin Pathol       Date:  2007-01-26       Impact factor: 3.411

2.  Fusion transcripts and transcribed retrotransposed loci discovered through comprehensive transcriptome analysis using Paired-End diTags (PETs).

Authors:  Yijun Ruan; Hong Sain Ooi; Siew Woh Choo; Kuo Ping Chiu; Xiao Dong Zhao; K G Srinivasan; Fei Yao; Chiou Yu Choo; Jun Liu; Pramila Ariyaratne; Wilson G W Bin; Vladimir A Kuznetsov; Atif Shahab; Wing-Kin Sung; Guillaume Bourque; Nallasivam Palanisamy; Chia-Lin Wei
Journal:  Genome Res       Date:  2007-06       Impact factor: 9.043

3.  ChiPPI: a novel method for mapping chimeric protein-protein interactions uncovers selection principles of protein fusion events in cancer.

Authors:  Milana Frenkel-Morgenstern; Alessandro Gorohovski; Somnath Tagore; Vaishnovi Sekar; Miguel Vazquez; Alfonso Valencia
Journal:  Nucleic Acids Res       Date:  2017-07-07       Impact factor: 16.971

4.  Different aneuploidies arise from the same bridge-induced chromosomal translocation event in Saccharomyces cerevisiae.

Authors:  Beatrice Rossi; Pawan Noel; Carlo V Bruschi
Journal:  Genetics       Date:  2010-08-30       Impact factor: 4.562

5.  A versatile reporter system for CRISPR-mediated chromosomal rearrangements.

Authors:  Yingxiang Li; Angela I Park; Haiwei Mou; Cansu Colpan; Aizhan Bizhanova; Elliot Akama-Garren; Nik Joshi; Eric A Hendrickson; David Feldser; Hao Yin; Daniel G Anderson; Tyler Jacks; Zhiping Weng; Wen Xue
Journal:  Genome Biol       Date:  2015-05-28       Impact factor: 13.583

6.  Integration of microarray analysis into the clinical diagnosis of hematological malignancies: How much can we improve cytogenetic testing?

Authors:  Jess F Peterson; Nidhi Aggarwal; Clayton A Smith; Susanne M Gollin; Urvashi Surti; Aleksandar Rajkovic; Steven H Swerdlow; Svetlana A Yatsenko
Journal:  Oncotarget       Date:  2015-08-07

7.  In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system.

Authors:  Danilo Maddalo; Eusebio Manchado; Carla P Concepcion; Ciro Bonetti; Joana A Vidigal; Yoon-Chi Han; Paul Ogrodowski; Alessandra Crippa; Natasha Rekhtman; Elisa de Stanchina; Scott W Lowe; Andrea Ventura
Journal:  Nature       Date:  2014-10-22       Impact factor: 49.962

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.